Get notified when SLBT files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Controlled Company (new) — CEO William Wang holds 59.53% voting power, allowing the company to opt out of key Nasdaq governance requirements.
  • Going Concern (new) — Auditor's report includes substantial doubt about the company's ability to continue as a going concern.
  • Customer Concentration (new) — Two customers accounted for 95.3% of 2025 revenue, with no minimum purchase agreements.
  • Single-source Supplier (new) — The company relies on one supplier, YC Biotech, for its exosome products.
  • Related-party Transactions (new) — CTO Dr. Ethan Shen owns 76% of JY BioMed, a licensor, and the company paid $455,714 to JY BioMed for R&D.
  • No Ind Filed (new) — The company has not filed an IND with the FDA, and the FDA declined its Orphan Drug Designation request.
  • Pcaob/hfcaa Delisting Risk (new) — The company's auditor is in Hong Kong, and if PCAOB inspections are restricted, the stock could be delisted.
NASDAQ: SLBT SL Science Holding Ltd 424B3

SL Science Holding (SLBT) completes $7.8M PIPE in SPAC merger; pre-clinical biotech with going concern doubt

Filed August 14, 2026 · ~2 min read

Key Changes

  • high

    SL Science Holding Ltd (SLBT) went public via SPAC merger with HSPT, closing June 12, 2026; the offering raised $7.8M gross from a PIPE of 780,000 units at $10.00 each.

    Notes to Consolidated Financial Statements verify on EDGAR →
  • high

    The company is pre-clinical: no FDA approvals, no INDs filed, and the FDA declined its Orphan Drug Designation request for its GBM product in May 2026.

    BUSINESS Overview view on EDGAR →
  • high

    GAAP net loss was $9.0M for the latest period; the company has an accumulated deficit of $5.48M and cash of $1.26M as of Dec 31, 2025.

    Notes to Financial Statements verify on EDGAR →

4 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (CALM 10-Q) is open in full — no account needed.

Partner

Trade SLBT commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov

Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify